Keytruda monotherapy meets in Phase III for first-line SCCHN

Merck & Co Inc. (NYSE:MRK) said first-line treatment with Keytruda pembrolizumab as monotherapy met the primary endpoint

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE